Clinical trial
A Phase 2 Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dose Levels of Subcutaneously Administered ELX-02 in Patients With Cystic Fibrosis With at Least One G542X Allele
NCT04135495 is registered in ClinicalTrials.gov with Eloxx Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dose Levels of Subcutaneously Administered ELX-02 in Patients With Cystic Fibrosis With at Least One G542X Allele
- Lead sponsor
- Eloxx Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 25, 2019
- Completion date
- October 3, 2022
- Enrollment
- 17 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.